Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 91,198 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph Lyssikatos sold 91,198 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.22, for a total transaction of $2,482,409.56. Following the completion of the sale, the insider owned 765,188 shares of the company’s stock, valued at approximately $20,828,417.36. The trade was a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded down $0.97 during trading hours on Monday, reaching $25.03. 1,373,161 shares of the company were exchanged, compared to its average volume of 2,697,186. The business has a 50 day moving average of $19.07 and a 200 day moving average of $19.95. Enliven Therapeutics, Inc. has a 1-year low of $13.30 and a 1-year high of $29.98. The company has a market capitalization of $1.49 billion, a P/E ratio of -13.60 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Commodore Capital LP boosted its holdings in shares of Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after acquiring an additional 17,809 shares in the last quarter. Polar Capital Holdings Plc raised its position in Enliven Therapeutics by 1.5% in the third quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock valued at $63,355,000 after purchasing an additional 44,713 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Enliven Therapeutics by 5.9% during the third quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after purchasing an additional 142,378 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Enliven Therapeutics by 364.0% during the third quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after purchasing an additional 910,000 shares in the last quarter. Finally, Duquesne Family Office LLC increased its stake in shares of Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock valued at $19,393,000 after buying an additional 484,405 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ELVN has been the topic of several recent analyst reports. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $41.00.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.